248 related articles for article (PubMed ID: 37507068)
1. Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.
Kuang FL; Khoury P; Weller PF; Wechsler ME; Klion AD
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2666-2671. PubMed ID: 37507068
[TBL] [Abstract][Full Text] [Related]
2. Biologic Agents for the Treatment of Hypereosinophilic Syndromes.
Kuang FL; Klion AD
J Allergy Clin Immunol Pract; 2017; 5(6):1502-1509. PubMed ID: 29122152
[TBL] [Abstract][Full Text] [Related]
3. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
Chen MM; Roufosse F; Wang SA; Verstovsek S; Durrani SR; Rothenberg ME; Pongdee T; Butterfield J; Lax T; Wechsler ME; Stein ML; Ogbogu PU; Kahwash BM; Mathur SK; Simon D; Akuthota P; Holland N; Wetzler L; Ware JM; Guo C; Fay MP; Khoury P; Klion AD; Bochner BS
J Allergy Clin Immunol Pract; 2022 May; 10(5):1217-1228.e3. PubMed ID: 35181548
[TBL] [Abstract][Full Text] [Related]
4. Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
[TBL] [Abstract][Full Text] [Related]
5. Approach to the patient with suspected hypereosinophilic syndrome.
Klion AD
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):47-54. PubMed ID: 36485140
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.
Helbig G; Kyrcz-Krzemień S
Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698
[TBL] [Abstract][Full Text] [Related]
7. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
Williams AK; Dou C; Chen LYC
Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
[TBL] [Abstract][Full Text] [Related]
8. Hypereosinophilic syndrome: an update.
Wilkins HJ; Crane MM; Copeland K; Williams WV
Am J Hematol; 2005 Oct; 80(2):148-57. PubMed ID: 16184589
[TBL] [Abstract][Full Text] [Related]
9. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
10. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
11. Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.
Reiter A; Lefevre G; Cid MC; Kwon N; Mavropolou E; Yancey SW; Steinfeld J
Front Immunol; 2022; 13():840974. PubMed ID: 35493455
[TBL] [Abstract][Full Text] [Related]
12. How I treat hypereosinophilic syndromes.
Klion AD
Blood; 2015 Aug; 126(9):1069-77. PubMed ID: 25964669
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.
Dispenza MC; Bochner BS
Curr Hematol Malig Rep; 2018 Jun; 13(3):191-201. PubMed ID: 29680938
[TBL] [Abstract][Full Text] [Related]
14. The hypereosinophilic syndromes: current concepts and treatments.
Gleich GJ; Leiferman KM
Br J Haematol; 2009 May; 145(3):271-85. PubMed ID: 19243381
[TBL] [Abstract][Full Text] [Related]
15. [Hypereosinophilic syndromes].
Groh M; Lefèvre G; Ackermann F; Étienne N; Kahn JE
Rev Prat; 2019 Sep; 69(7):767-773. PubMed ID: 32233322
[TBL] [Abstract][Full Text] [Related]
16. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
[TBL] [Abstract][Full Text] [Related]
17. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.
Dahabreh IJ; Giannouli S; Zoi C; Zoi K; Voulgarelis M; Moutsopoulos HM
Medicine (Baltimore); 2007 Nov; 86(6):344-354. PubMed ID: 18004179
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
Kuang FL; Fay MP; Ware J; Wetzler L; Holland-Thomas N; Brown T; Ortega H; Steinfeld J; Khoury P; Klion AD
J Allergy Clin Immunol Pract; 2018; 6(5):1518-1527.e5. PubMed ID: 29751154
[TBL] [Abstract][Full Text] [Related]
19. Management of Hypereosinophilic Syndromes.
Roufosse F
Immunol Allergy Clin North Am; 2015 Aug; 35(3):561-75. PubMed ID: 26209900
[TBL] [Abstract][Full Text] [Related]
20. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
